728 results on '"Bruns R"'
Search Results
2. Autonomes elektronisches Lenksystem als Basis für die Automatisierung des Routenzuges
3. PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C
4. OA01.08 Clinical Response to Tepotinib According to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced/Metastatic NSCLC with High-level MET Amplification (METamp) Detected by Liquid Biopsy (LBx)
5. PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
6. Effect of a gas–gas-heater on H2SO4 aerosol formation: Implications for mist formation in amine based carbon capture
7. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
8. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
9. Flurförderzeuge
10. Stetigförderer
11. 985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
12. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
13. Fördertechnik
14. Impfung von Kindern mit erhöhtem Allergierisiko: Kurzfassung des Positionspapiers „Allergie und Impfen“ der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin
15. R&D in material protection: New biocides
16. Industrial trucks
17. Febrile ulceronecrotic Mucha–Habermann disease following suspected hemorrhagic chickenpox infection in a 20-month-old boy
18. S3-Leitlinie „Lungenerkrankung bei Mukoviszidose“: Modul 1: Diagnostik und Therapie nach dem ersten Nachweis von Pseudomonas aeruginosa
19. 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy
20. 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
21. Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
22. Tepotinib in Patients with Advanced NSCLC with MET Amplification (METamp)
23. Einflüsse von Reibung und Spiel in passiven und semiaktiven Sitzfederungen auf den objektiven Fahrkomfort
24. Yield and stability factors associated with hybrid wheat
25. Structure Activity Relationships for Adenosine Antagonists
26. P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
27. P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
28. 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
29. PD-020 Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib
30. The readability of English medium curriculum texts in Brunei primary schools.
31. Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression (British Journal of Cancer, (2021), 10.1038/s41416-021-01334-9)
32. Peanut���induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry
33. 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
34. 1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
35. 157P Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A
36. P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
37. FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
38. MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
39. Effects of experimental conditions on the estimation of kinetic parameters of the thermal decomposition of AZT using factorial design
40. Molecular and clinical characteristics of respiratory syncytial virus infections in hospitalized children
41. OA05.03 Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A
42. MO01.46 Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC
43. MO01.45 Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib
44. 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
45. 34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
46. Stetigförderer
47. Flurförderzeuge
48. A statistically designed study of ternary electrolyte polymer material (PEO/LIClO4/ethylene carbonate)
49. 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
50. 1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.